How Weight-Loss Drugs Are Changing Employer Health Benefits in Canada (2025 Guide)

Weight-loss drugs like Wegovy and Ozempic are changing Canadian workplace health benefits. Learn how employers can manage costs, design smarter plans, and support employee wellbeing in 2025.

Canadian employers are heading into 2025 with a new challenge that could reshape the future of workplace benefits: weight-loss drugs. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide have quickly moved from niche treatments to mainstream options for obesity management. While these drugs hold promise for improving employee health, they also raise difficult questions about cost, coverage, and long-term plan sustainability.

For HR and benefits leaders, the rise of weight-loss drugs is no longer a distant issue. Employees are already asking about coverage, insurers are adjusting policies, and costs are beginning to climb. Understanding what’s driving this shift is essential for employers who want to stay ahead.

The Rising Cost Pressures on Employer-Sponsored Health Plans in Canada

Health benefits in Canada were already under pressure before GLP-1 medications entered the picture. Aging populations, chronic diseases, and costly specialty drugs have steadily pushed employer plan costs upward. Now, weight-loss medications are poised to amplify the trend.

Canada’s Medical Trend Outlook for 2025

A new Aon Canada report projects employer medical costs will increase 7.4% in 2025, compared with 5% in 2024. This jump is driven largely by prescription drug claims, with obesity treatments highlighted as an emerging factor.

Employers that already struggle with balancing affordability and access will face harder choices in the year ahead. Without new plan design strategies, rising claims could quickly outpace budgets.

Obesity and Chronic Disease as Cost Drivers

Obesity is a recognized chronic disease in Canada and is linked to a wide range of costly health conditions, including diabetes, cardiovascular disease, and certain cancers. The Public Health Agency of Canada reports that almost 1 in 4 Canadian adults is classified as obese, a prevalence that has remained stubbornly high.

For employers, this translates into increased prescription drug claims, more disability leaves, and productivity losses. While weight-loss drugs may help reduce long-term risks, they come with high upfront costs and uncertain patterns of sustained use.

Why Insurers Flag GLP-1s as an Emerging Risk

Insurers and benefits consultants are already warning employers about the implications of covering weight-loss medications. Key risks include:

• Ongoing therapy: Many patients need to stay on GLP-1 drugs indefinitely, leading to recurring, high annual costs.
• Off-label use: Drugs approved for diabetes are sometimes prescribed for weight loss, creating compliance and cost-management challenges.
• Adverse selection: Plans that cover these medications may attract employees more likely to claim, skewing risk pools.

As a result, insurers are rolling out tighter controls such as prior authorization, eligibility rules, and annual limits. Employers will need to decide how much flexibility to build into their plans and whether the potential health benefits outweigh the financial risks.

GLP-1 and Obesity Drugs: The New Frontier in Benefits Coverage

Employers now face a tough question: if obesity is a chronic disease, should weight-loss drugs be treated like any other therapy? This section looks at the science, regulatory background, and early employer adoption trends.

What Are GLP-1, Semaglutide & Tirzepatide?

GLP-1 (glucagon-like peptide-1) is a hormone that helps regulate blood sugar and appetite. Drugs that mimic GLP-1 (called agonists) slow digestion, curb hunger, and enhance insulin response. The clinical result is sustained weight loss and improved metabolic profiles.

In Canada, Wegovy® (semaglutide 2.4 mg) is approved for chronic weight management when paired with diet and exercise. It is now also indicated to reduce the risk of non-fatal heart attacks in patients with overweight plus cardiovascular disease. That makes it the first obesity drug in Canada with that dual indication.
(Novo Nordisk’s press release notes Health Canada’s expanded approval)

Tirzepatide (sold under names like Zepbound™) acts on both GLP-1 and GIP (another hormone), potentially offering stronger weight-loss effects. Obesity Canada lists both semaglutide and tirzepatide among the prescription medications used for long-term weight management in Canada.

Other approved obesity drugs include liraglutide (Saxenda®), naltrexone/bupropion (Contrave®), and orlistat (Xenical®), each with different mechanisms and effectiveness.

Regulatory & Coverage Status in Canada

Health Canada’s Approval Paths
Health Canada granted approval for Wegovy in the past few years, and later in 2024, it expanded the label to include reduction in non-fatal myocardial infarction risk in certain patients. This broader cardiovascular benefit gives employers more clinical justification to consider coverage.
(See Health Canada’s regulatory decision summary for Wegovy)

The Canadian Dental Association / Canadian Medical Association has also published supporting information confirming semaglutide’s approval as adjunct therapy for chronic weight management.

Private Drug Plan Landscape
Despite regulatory approval, actual coverage through private insurers and employer plans remains limited. Obesity Canada notes that fewer than 20 % of private drug plans currently cover obesity medications in Canada.

A 2025 survey by the International Foundation of Employee Benefit Plans found that 31 % of Canadian employers now offer GLP-1 coverage for both diabetes and weight loss (up from 17 % in 2024). Among those that offer coverage, many employ cost controls such as eligibility requirements (45 %) and annual maximums (32 %). All who offer these drugs use prior authorization.

Interestingly, most employers (86 %) integrate GLP-1s into their standard prescription drug plans; others use health spending accounts (27 %) or supplemental riders (14 %).

Trends in Employer Adoption

Adoption is accelerating—but cautiously. Key trends include:

• Employers tightening controls around eligibility and prescribing pathways
• Growing use of utilization management (prior authorization, reauthorization, physician-led review)
• Some employers pilot restricted coverage (e.g. for high-BMI segments)
• Insurers push back on full unrestricted coverage due to long-term cost concerns

A Benefits Canada article reports that plan sponsors and insurers are actively discussing how to manage the growth in semaglutide/Ozempic claims, adding prior authorization to restrict off-label use and adjusting adjudication rules.

Also, generic versions of semaglutide are anticipated in Canada in early 2026, which could shift coverage economics. According to WTW’s 2025 insights, as generics enter the market, many employers are re-evaluating their benefit designs and preparing for price disruption.

Models for Employer Coverage of Weight-Loss Drugs

As interest in GLP-1 therapies grows, Canadian employers are experimenting with different ways to add coverage without breaking their budgets. The right approach depends on the workforce profile, plan design, and tolerance for financial risk.

Full Integration Into Prescription Drug Plans

Some employers choose to cover weight-loss drugs in the same way they cover diabetes or hypertension medications. This “all in” model offers employees the most straightforward access and avoids the stigma of treating obesity differently.

Pros:

• Simplicity in administration
• Strong message of employer support for health equity
• Potential to reduce long-term chronic disease costs

Cons:

• High risk of rapid cost escalation
• Difficult to forecast future claims
• May require higher premiums or employee cost sharing

Partial or Rider Coverage

Another approach is to add weight-loss drug coverage as an optional rider or carve-out benefit. Employees who anticipate needing the drugs can opt in, sometimes paying an additional premium.

Pros:

• Spreads cost between employer and employee
• Allows employers to offer coverage without full liability
• Provides a middle ground for cautious organizations

Cons:

• May create adverse selection if only high-risk employees enroll
• Can increase plan administration complexity

Health Spending Accounts and Trusts

Health Spending Accounts (HSAs) and Health & Welfare Trusts give employers more flexibility. Because these accounts are tax-advantaged, employees can use them to reimburse prescription drug expenses, including GLP-1s, subject to plan rules.

The Canada Revenue Agency recognizes prescription medications as eligible medical expenses under HSAs, which means employers can provide coverage without fully restructuring the core drug plan.

Advantages:

• Flexible, tax-efficient coverage
• Employees choose how to allocate funds
• Helps limit employer’s maximum financial exposure

Challenges:

• Annual HSA limits are often much lower than GLP-1 costs
• Employees may see coverage as insufficient if funds run out mid-year

Managed Benefit Design Levers

Many employers are implementing stricter controls to manage utilization and prevent misuse. Common levers include:

• Prior authorization: requiring documentation of BMI, comorbidities, or unsuccessful lifestyle interventions
• Step therapy: asking employees to try lower-cost treatments before GLP-1s
• Reauthorization: periodic review to confirm ongoing medical need and adherence
• Prescriber restrictions: limiting approval to endocrinologists or obesity specialists
• Annual maximums: capping benefits at a set dollar amount per member

These tools allow employers to balance access with sustainability, ensuring drugs go to those most likely to benefit.

Managing Cost and Risk: Employer Tactics and Strategies

Covering weight-loss drugs can improve employee health, but without careful guardrails, costs may spiral. Canadian employers are now experimenting with a mix of data-driven analysis, plan design changes, and employee support programs.

Data Analytics and Forecasting

Before introducing coverage, many organizations start with claim modeling. By analyzing demographics, BMI distribution, and comorbidity rates, employers can estimate potential uptake and cost.

Benefits consultants often run scenarios showing the incremental cost per member per year under different eligibility criteria. For example, restricting coverage to employees with both obesity and diabetes produces far lower projected spend than open eligibility.

Cost-Sharing Mechanisms

Employers are also shifting part of the cost to employees. Common approaches include:

• Coinsurance (e.g., 20–30% employee share)
• Annual or lifetime maximums
• Tiered copays, where GLP-1s are in a higher specialty tier
• Differential premiums, where employees who want expanded coverage pay more

This balance can help plans remain sustainable while still offering access.

Utilization Controls and Guardrails

Insurers in Canada are recommending stricter controls around GLP-1 prescribing. Typical measures include:

• Prior authorization: requiring proof of BMI ≥30, or ≥27 with comorbidities
• Step therapy: trying lifestyle modification or other treatments first
• Reauthorization: ongoing coverage dependent on documented weight-loss progress
• Prescriber restrictions: limiting initial prescribing to endocrinologists or obesity specialists

These measures mirror approaches already common in the United States, where employer adoption is further ahead.

Employee Education and Adherence Support

Simply covering a drug does not guarantee outcomes. Employers are pairing medication access with education and wellness programs.

Some insurers bundle coaching, nutrition counseling, and virtual care into benefit packages. The aim is to support long-term lifestyle changes, which in turn can improve adherence and reduce relapse once employees stop taking the drug.

Measuring ROI and Health Outcomes

The business case for covering GLP-1 drugs hinges on return on investment (ROI). Employers are tracking:

• Reductions in diabetes and cardiovascular claims
• Lower disability and absenteeism rates
• Employee satisfaction and retention

Early research from Aon’s GLP-1 research findings suggests measurable improvements in workforce health outcomes, though costs remain substantial. Employers adopting phased rollouts or pilot programs are best positioned to measure ROI before committing to broader coverage.

Case Studies and Employer Examples

Several Canadian insurers are beginning to test new approaches. For example, Saskatchewan Blue Cross added Wegovy to its formulary in 2024 under special authorization, allowing access for employees who meet strict eligibility criteria.

In the United States, where adoption is further advanced, nearly one-third of large employers now cover GLP-1s for both diabetes and weight loss. Surveys reported by Benefits Canada show employers relying heavily on prior authorization and cost caps to keep spending under control. Canadian employers are watching these lessons closely.

Challenges, Risks and Precautions

While the benefits of weight-loss drugs are clear, several risks remain:

• Clinical uncertainty: Long-term safety data is still emerging, and discontinuation often leads to weight regain.
• Adverse selection: Coverage may attract employees more likely to claim, increasing plan imbalance.
• Administrative complexity: Prior authorization and reauthorization add workload for HR and insurers.
• Workforce communication: Employers must balance employee expectations with fiscal responsibility.

Ignoring these challenges could undermine both the financial sustainability of plans and employee trust.

A Roadmap for Canadian Employers

Employers considering weight-loss drug coverage can take a phased approach:

1. Frame obesity as a medical condition and gain leadership buy-in.
2. Audit employee health data to estimate likely utilization.
3. Engage insurers or consultants with experience in GLP-1 plan design.
4. Pilot coverage with eligibility restrictions and measurable goals.
5. Track outcomes on health claims, absenteeism, and employee satisfaction.
6. Communicate clearly with employees about rules, limits, and available supports.

This roadmap ensures a balance between access, cost control, and health improvement.

Conclusion: Balancing Access and Sustainability

Weight-loss drugs are no longer on the margins of Canadian healthcare—they are at the centre of workplace benefits discussions. Employers face rising costs but also a unique opportunity to improve employee health outcomes.

The best approach is balanced: offer coverage where clinically justified, manage costs through smart plan design, and support employees with education and lifestyle resources. Done well, weight-loss drug coverage can help employers control long-term risks, improve workforce wellbeing, and strengthen their position as competitive, supportive workplaces.

For organizations exploring next steps, this is the time to run a pilot, gather data, and speak with advisors. The decisions made in 2025 will shape how employer health benefits evolve for years to come.

FAQ